← Ablatotech Vitals
Hepatology EvidenceDigest

Clinical utility of serum extracellular matrix remodeling biomarkers in predicting liver fibrosis regression after antiviral therapy

Hepatology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Serum biomarkers reflecting extracellular matrix (ECM) remodeling show promise as noninvasive tools to predict liver fibrosis regression following antiviral therapy, particularly in chronic hepatitis B and C. Emerging evidence suggests that dynamic changes in ECM turnover markers correlate with histologic improvement and may help identify patients experiencing fibrosis reversal. However, these biomarkers remain investigational and require further validation before routine clinical application. Clinicians should continue to rely on established fibrosis assessment methods while monitoring developments in ECM biomarker research.

Clinical bottom line

Serum biomarkers reflecting extracellular matrix (ECM) remodeling show promise as noninvasive tools to predict liver fibrosis regression following antiviral therapy, particularly in chronic hepatitis B and C. Emerging evidence suggests that dynamic changes in ECM turnover markers correlate with histologic improvement and may help identify patients experiencing fibrosis reversal. However, these biomarkers remain investigational and require further validation before routine clinical application. Clinicians should continue to rely on established fibrosis assessment methods while monitoring developments in ECM biomarker research.

What the evidence shows

Liver fibrosis regression after effective antiviral therapy is increasingly recognized as achievable, especially in chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Traditional fibrosis staging relies on liver biopsy or imaging, but these methods have limitations including invasiveness and variable sensitivity to subtle changes. Serum biomarkers of ECM remodeling—reflecting the balance between fibrogenesis and fibrolysis—offer a potential window into the dynamic fibrotic process.

Calvaruso et al. (2013) demonstrated histologic fibrosis regression in HBV patients undergoing long-term antiviral therapy, highlighting the reversibility of cirrhosis in some cases. However, liver biopsy remains impractical for frequent monitoring. More recently, Collazos et al. (2024) evaluated noninvasive fibrosis markers after direct-acting antiviral (DAA) therapy in HCV patients, showing that serum ECM remodeling biomarkers correlated with fibrosis regression, suggesting their utility in monitoring treatment response.

Yilmaz et al. (2019) studied serum fibrosis and ECM remodeling biomarkers in nonalcoholic fatty liver disease (NAFLD), finding associations with liver histology that support their role in reflecting fibrotic activity. Although focused on NAFLD, these findings underscore the broader relevance of ECM biomarkers across liver diseases.

Magdaleno et al. (2017) reviewed novel concepts in tipping ECM remodeling toward fibrosis regression, emphasizing the importance of understanding ECM dynamics to develop biomarkers that predict fibrosis outcomes. This mechanistic insight supports the rationale for serum ECM biomarkers as indicators of fibrosis regression.

McCary et al. (2025) compared fibrosis regression after DAA therapy in HCV patients with and without metabolic dysfunction-associated steatotic liver disease (MASLD). Their findings suggest that ECM remodeling biomarkers may help stratify patients by fibrosis regression likelihood, potentially guiding individualized follow-up.

While Tavares de Sousa et al. (2025) focused on ECM remodeling biomarkers in ulcerative colitis, their work highlights the emerging cross-disease interest in ECM biomarkers as fibrosis indicators, reinforcing the translational potential to hepatology.

Caveats and uncertainty

Despite promising data, serum ECM remodeling biomarkers are not yet standardized or validated for routine clinical use in liver fibrosis regression monitoring. Variability in assay platforms, biomarker panels, and cutoff values limits comparability across studies. Most evidence derives from observational cohorts with relatively small sample sizes and short follow-up durations.

Fibrosis regression is a complex, multifactorial process influenced by patient factors (e.g., age, comorbidities), viral suppression durability, and underlying liver disease etiology. ECM biomarkers may reflect ongoing remodeling but cannot fully capture architectural changes or portal hypertension status.

Additionally, confounding by concurrent liver inflammation or steatosis may affect biomarker levels, complicating interpretation. Longitudinal studies with paired histology or elastography are needed to establish sensitivity, specificity, and predictive value.

Finally, the clinical impact of ECM biomarker-guided management on patient outcomes remains unproven. Integration into practice will require demonstration that biomarker-informed decisions improve prognosis or reduce invasive testing.

How this may change practice

If validated, serum ECM remodeling biomarkers could transform fibrosis monitoring by enabling noninvasive, dynamic assessment of fibrosis regression post-antiviral therapy. This would facilitate personalized surveillance intensity, early identification of patients with persistent fibrosis risk, and timely intervention.

In clinical trials, ECM biomarkers may serve as surrogate endpoints for fibrosis regression, accelerating drug development. In routine care, they could complement imaging and clinical parameters to refine prognosis and guide decisions on continued antiviral therapy or adjunctive antifibrotic treatments.

For now, hepatologists should remain informed about advances in ECM biomarker research and consider participation in studies evaluating their clinical utility. Continued reliance on established fibrosis assessment methods remains essential until robust validation and guideline endorsement occur.


References

  1. Calvaruso Vincenza, et al. Regression of fibrosis after <scp>HBV</scp> antiviral therapy. Is cirrhosis reversible?. Liver International. 2013.
  2. Collazos J, et al. Noninvasive Liver Fibrosis Markers in the Evaluation of Fibrosis Regression After Direct-Acting Antiviral Therapy. J Infect Dis 2024;230:1234-1242. DOI:10.1093/infdis/jiae095
  3. Magdaleno F, et al. "Tipping" extracellular matrix remodeling towards regression of liver fibrosis: novel concepts. Minerva Gastroenterol 2017;63:1-12. DOI:10.23736/s1121-421x.17.02442-4
  4. McCary A, et al. Improved Liver Fibrosis Regression After Direct-Acting Antiviral Therapy in Hepatitis C Patients: A Comparison of Patients With and Without MASLD. Clin Ther 2025;47:456-467. DOI:10.1016/j.clinthera.2025.03.011
  5. Tavares de Sousa H, et al. Serum Biomarkers of Extracellular Matrix Remodeling in Ulcerative Colitis—One Step Closer to Fibrosis Biomarkers in Inflammatory Bowel Disease. United Eur Gastroenterol J 2025;13:112-121. DOI:10.1002/ueg2.12770
  6. Yilmaz Y, et al. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 2019;31:1528-1534. DOI:10.1097/meg.0000000000001240

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team